Disappointment at lack of reimbursement for CRC drugs
Transcript of Disappointment at lack of reimbursement for CRC drugs
PharmacoEconomics & Outcomes News 695, p10 - 1 Feb 2014
Disappointment at lack ofreimbursement for CRC drugs
The Colorectal Cancer Association of Canada (CCAC)is "very concerned" that new drugs for the treatment ofmetastatic colorectal cancer (mCRC) have not beenrecommended for public funding.
Both regorafenib [Stivarga] and cetuximab [Erbitux]failed to be recommended by the pan-CanadianOncology Drug Review (pCODR) – a decision whichwas a "great disappointment to patients, caregivers andthe colon cancer community". President of the CCAC,Barry Stein, says that "the cost of these new products canbe high, however, the benefit to society and to patientsof developing these new drugs should not be such thatpatients lose the opportunity to benefit from them dueto their cost alone".Colorectal Cancer Association of Canada. Canadians are still frustrated at lack ofaffordable access to new cancer medicines. Media Release : 27 Jan 2014.Available from: URL: http://www.colorectal-cancer.ca 809158710
1
PharmacoEconomics & Outcomes News 1 Feb 2014 No. 6951173-5503/14/0695-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved